ReviewCurrent atherosclerosis reports2011
Developmental mechanisms involved in the primary prevention of atherosclerosis and cardiovascular disease.
Review in Current atherosclerosis reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biomarkers and Gene Polymorphisms in Members of Long- and Short-lived Families: A Longevity Study.The open cardiovascular medicine journal · 2018Article
- Epigenetic reprogramming in atherosclerosis.Current atherosclerosis reports · 2015Review
- Antioxidants, inflammation and cardiovascular disease.World journal of cardiology · 2014Review
- Proinflammatory and prothrombotic state in subjects with different glucose tolerance status before cardiovascular disease.Journal of diabetes research · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The common belief that signs of atherosclerosis and cardiovascular disease (CVD) are clinically relevant only during adult and elderly age is gradually changing. Increasing evidence supports the concept that CVD is initiated through developmental in utero processes beginning before birth. Epigenetic and other unknown mechanisms underlying these developmental events are yet to be elucidated. The clinical implications of such theories for the primary prevention of CVD are intuitive and logical, but clinical prospective studies and translational approaches are still warranted. The evolution of CVD is usually characterized by a long lag time between onset and clinical manifestation, thereby providing a relevant opportunity for its early non-invasive detection during childhood and tailored therapeutic strategies, both with established pharmacologic agents and newly developed drugs that can affect epigenetic mechanisms.
Indexed as
Identifiers
21221859What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.